First Eagle Investment Management
AST

First Eagle Investment Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

First Eagle Investment Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-63,038
Closed -$425K – 354
2015
Q1 		$425K Sell
63,038
-84,800
-57% -$420K ﹤0.01% 252
2014
Q4 		$478K Buy
+147,838
New +$595K ﹤0.01% 253

Other funds holding AST

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

First Eagle Investment Management's AST Position: Q2 2015 in Review

First Eagle Investment Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2015, closing a stake of 63,038 shares — an estimated $425K sold.

First Eagle Investment Management first reported a position in AST in Q4 2014 and held it in 2 quarters. The position peaked at $478K in Q4 2014. 63 funds tracked by Wall St. Rank hold AST as of Q2 2015.

  • First Eagle Investment Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2015 after selling out during the quarter.
  • First Eagle Investment Management sold 63,038 Asterias Biotherapeutics Inc. Series A shares in Q2 2015, an estimated $425K.
  • First Eagle Investment Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 2 quarters.
  • First Eagle Investment Management's Asterias Biotherapeutics Inc. Series A position peaked at $478K in Q4 2014.
  • 63 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2015.

Based on First Eagle Investment Management's 13F filing for Q2 2015, filed 12 Aug 2015.